Last Updated : June 21, 2024
Details
FilesGeneric Name:
lecanemab
Project Status:
Received
Therapeutic Area:
Alzheimer’s disease
Manufacturer:
Eisai Canada
Call for patient/clinician input open:
Brand Name:
Leqembi
Project Line:
Reimbursement Review
Project Number:
SR0822-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Lecanemab is a
disease-modifying treatment for adult patients with Alzheimer’s disease.
Treatment with lecanemab should be initiated in patients with mild cognitive
impairment or mild dementia stage of disease. Patients must have documented
presence of amyloid beta pathology. Lecanemab should be prescribed by
clinicians with expertise in diagnosing, managing and treating patients with mild cognitive
impairment or mild dementia stage of disease (early AD).
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Lecanemab is indicated as a disease-modifying
treatment in adult patients with Alzheimer’s disease. Treatment with lecanemab
should be initiated in patients with mild cognitive impairment or mild dementia
stage of disease.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Call for patient/clinician input open | 25-Apr-24 |
---|---|
Call for patient/clinician input closed | 17-Jun-24 |
Submission received | 14-Jun-24 |
Submission accepted | - |
Files
Last Updated : June 21, 2024